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Bismuth coordination networks containing
deferiprone: synthesis, characterisation, stability
and antibacterial activity†
Andrew D. Burrows,*a Monika Jurcic,a Mary F. Mahon,*a Sandrine Pierrat,a
Gavin W. Roﬀe,b Henry J. Windlec and John Spencer*b
A series of bismuth–dicarboxylate–deferiprone coordination net-
works have been prepared and structurally characterised. The new
compounds have been demonstrated to release the iron overload
drug deferiprone on treatment with PBS and have also been shown
to have antibacterial activity against H. pylori.
Coordination network structures have attracted considerable
attention in recent years.1,2 Although much of this interest has
arisen from the capacity of this type of material to store gases
within the pores, there has been an increasing interest in the
inclusion of larger, more complex molecules including those
with biological activity. Thus, metal–organic frameworks
(MOFs) capable of storing drug molecules within pores and
delivering these to an organism have been developed.3 An
alternative strategy makes use of the active ingredient as a
ligand bound to the metal within the framework.4–8 In this
case, there is no requirement for the framework to be porous,
and conceptually, a plasma-stable MOF could be fine-tuned
for oral delivery, as a suspension, releasing the bioactive cargo
under conditions (e.g. pH) which digest the framework struc-
ture into its constituent parts.
Recently, we reported a series of zinc-based MOFs9 contain-
ing deferiprone,10 an iron overload drug, as an anionic chelat-
ing ligand. Immediate decomposition, and deferiprone
release, was eﬀected under mild conditions including in PBS
(phosphate buﬀered saline) or dilute hydrochloric acid.
Bismuth compounds such as bismuth subsalicylate (BSS)
and ranitidine bismuth citrate (RBC) are generally poorly
soluble and structurally ill-defined, but despite this, they are
eﬀective, orally-delivered drugs.11–15 When combined with
antibiotics, (RBC also comprises a H2-antagonist, ranitidine),
such drugs are extremely eﬀective against Helicobacter pylori,
which is implicated in peptic ulcers, gastritis and gastric
cancers.16 Studies have elucidated the role of bismuth in inter
alia disrupting enzymes such as urease (aﬀecting nickel
homeostasis and acid acclimation), mimicking iron depri-
vation and inhibiting cellular ATP synthesis.17 Antibacterial
bismuth compounds are now finding biomedical uses such as
in dental implants and haemodialysis catheters.18,19
The above uses and structural complexity of bismuth-based
materials has prompted us to extend our studies to include
bismuth complexes as model compounds for potential drug
delivery and biomedical applications. It has been previously
demonstrated that bismuth dicarboxylates can form coordi-
nation network structures.20–22 We therefore reasoned that it
might be possible to include deferiprone into such structures,
with the resultant compounds having a potential dual action
mode. To this end we have investigated the formation and
structures of bismuth–dicarboxylate–deferiprone complexes,
then looked at their stability in terms of acting as deferiprone
sources and also their activity against H. pylori.
The product from the reaction between bismuth(III) nitrate
pentahydrate, 1,4-benzenedicarboxylic acid (H2bdc) and deferi-
prone (Hdfp) depends crucially on the Bi(NO3)3·5H2O : Hdfp
ratio employed, with a mixture of DMF and water as solvent
giving the best crystals. When the reaction is carried out with
the Bi(NO3)3·5H2O : Hdfp ratio 1 : 1, the product consists of
more than one phase, though pale yellow single crystals of
[Bi2(bdc)2(dfp)2]·DMF 1 can readily be manually separated
from grey/cream powders. When the reaction is carried out
with the Bi(NO3)3·5H2O : Hdfp ratio 1 : 4, the reaction yields
solely pale yellow crystals of [Bi2(bdc)(dfp)4(H2O)2]·2DMF 2.
Both 1 and 2 were characterised by X-ray crystallography,
with powder X-ray diﬀraction confirming phase purity and
1H NMR spectroscopy of the acid-digested samples confirming
that the bdc : dfp ratio in the bulk is the same as that in the
crystals.
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Reactions were also undertaken with the substituted
dicarboxylic acids 2-amino-1,4-benzenedicarboxylic acid
(H2bdc-NH2) and 2,5-dihydroxy-1,4-benzenedicarboxylic acid
(H2bdc-(OH)2). In both cases, the reactions with a 1 : 1 ratio of
Bi(NO3)3·5H2O : Hdfp gave mixed phases without single
crystals analogous to those of 1, but reactions with a 1 : 4 ratio
of Bi(NO3)3·5H2O : Hdfp gave [Bi2(bdc-NH2)(dfp)4(H2O)2]·2DMF
3 and [Bi2{bdc-(OH)2}(dfp)4(H2O)2]·2DMF 4, both of which are
isostructural to 2.
The asymmetric unit of 1 consists of a bismuth centre, a
dfp ligand and a bdc ligand, with residual electron density
approximating to half of a molecule of DMF per bismuth
centre. This gives rise to a formula for 1 of [Bi(bdc)-
(dfp)]·0.5DMF. The bismuth centre forms six Bi–O contacts
less than 2.65 Å, with coordination to a bidentate dfp ligand
and two bidentate carboxylates. Three longer Bi–O contacts,
between 2.85 Å and 2.95 Å, connect the bismuth centres into
Bi-dfp-carboxylate chains (Fig. 1a). The dfp and carboxylate
groups therefore adopt μ–κ1,κ2 coordination modes, and
overall the bismuth centre is 9-coordinate. The Bi-dfp-carboxy-
late chains are linked together by the benzene rings of the bdc
ligands to form sheets (Fig. 1b). The dfp ligands project
approximately perpendicular to these sheets, and those on
neighbouring sheets interdigitate, though they are suﬃciently
oﬀset to ensure there is no significant π-stacking. The dfp
ligand atoms, oxygens excepted, are evenly disordered over two
sites.
Compounds 2, 3 and 4 are isostructural, so only the struc-
ture of 2 will be described in detail. The asymmetric unit of 2
is composed of one bismuth centre, two dfp ligands, half of a
bdc ligand, one included water molecule and one included
DMF molecule. A centre of symmetry generates the remainder
of the bdc ligand. The bismuth centre is coordinated to two
bidentate dfp ligands and a bidentate carboxylate group,
forming six Bi–O bond distances of less than 2.75 Å.
Additional longer Bi–O contacts are present, with a bond to a
carboxylate [Bi(1)–O(2)′ 3.046(6) Å] linking the bismuth centres
into carboxylate-bridged dimers and a bond to a water mole-
cule [Bi(1)–O(7) 3.159(7) Å] meaning that the bismuth centres
are best described as eight-coordinate (Fig. 2a). Overall, the
formula for 2 is [Bi2(dfp)4(bdc)(H2O)2]·2DMF.
The bdc ligands bridge between the Bi2(dfp)4(O2CR)2(H2O)2
units, linking these into chains running along the crystallo-
graphic a axis, as shown in Fig. 2b. There is also oﬀset π-stack-
ing within the structure, with dfp⋯bdc⋯dfp interactions
present between the ligands within each chain [3.3 Å]
and dfp⋯dfp interactions present between the ligands in
neighbouring chains [3.2 Å], serving to connect the chains into
sheets. Hydrogen bonding is observed with the included water
molecule acting as a hydrogen bond donor to both a dfp
ligand and the included DMF molecule.
Previous studies on the use of zinc-based MOFs as a poten-
tial drug release platform for deferiprone showed immediate
release in phosphate buﬀered saline (PBS) and HCl-PBS buﬀer
(pH 5.5) as monitored by LCMS. Compounds 2 and 4 were
Fig. 1 The structure of [Bi(bdc)(dfp)]·0.5DMF 1, showing (a) the Bi-dfp-
carboxylate chains, and (b) interdigitation of the sheets. Disorder
omitted for clarity.
Fig. 2 The structure of [Bi2(bdc)(dfp)4(H2O)2]·2DMF 2, showing (a) the
Bi2(dfp)4(carboxylate)2H2O)2 dimers, and (b) the chains formed by linking
together the dimers.
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selected for analysis, and their stability studies were under-
taken using 1H NMR spectroscopy and LCMS.
[Bi2(bdc)(dfp)4(H2O)2]·2DMF 2 showed fast release of deferi-
prone in D2O in NMR studies, which was mirrored in LCMS
studies in PBS, over a period of 5 h (Fig. 3, also see ESI†). Inter-
estingly, the deferiprone was released so rapidly in each
respective medium that the 1H NMR spectrum and LCMS trace
taken immediately after addition already showed significant
release. Identical studies were undertaken with [Bi2{bdc-(OH)2}-
(dfp)4(H2O)2]·2DMF 4, and these showed no detectable release
of deferiprone from D2O over a period of 24 h, and signifi-
cantly slower release than 2 in PBS as confirmed by LCMS
(Fig. 3). To investigate the release of Hdfp from 4 using acid
digestion, the LCMS trace was initially taken in PBS, showing
little release, followed by HCl-PBS (pH 2) where substantial
release was observed.
Compounds 2 and 4 were also tested against H. pylori
(strain SS1) and compared with a positive control, bismuth
subsalicylate (BSS). Diﬀerent amounts of the compounds (0, 1,
2, 4, 8, 10 20 μg ml−1) were used to test their bacteriostatic and
bactericidal activities. This was determined by spreading a
lawn of an appropriately diluted suspension (post-exposure to
the compounds for 24 h in brain heart infusion broth sup-
plemented with foetal calf serum (10%, v/v) under microaero-
bic conditions) of the bacteria on Columbia blood agar plates
followed by colony counting. Fig. 4 shows just the optical
density readings (600 nm) of the bacterial suspensions 24 h
post-treatment; as reduced readings relative to the control
could represent either bactericidal or bacteriostatic activity the
minimum inhibitory concentration (MIC) was determined.
Both 2 and 4 showed MIC values of less than 10 μg ml−1. In
comparison, BSS showed a MIC value of less than 4.0 μg ml−1.
This indicates that 2 and 4 have appreciable H. pylori inhibi-
tory action, comparable to that of BSS.
Conclusions
We have demonstrated that deferiprone can be incorporated as
a terminal bidentate ligand into one- and two-dimensional
bismuth coordination networks, and that it can be released on
treatment with acid or PBS. Notably, the substituents on the
1,4-benzenedicarboxylate ligands play an important role in the
rate of deferiprone release, with 2,5-dihydroxy substituents sig-
nificantly retarding this. The reasons for this are currently
under investigation. The coordination networks also show
appreciable antibacterial activity, as demonstrated by inhi-
bition of H. pylori growth. This potential dual mode of action,
with both the ligand and metal centre playing diﬀerent bio-
logical roles, has broad significance for other systems. Current
work is focussing on removing the requirement for DMF in the
syntheses and further retarding the rate of dissolution of the
compounds in PBS as we move from the current model
systems into compounds that are more suitable for in vivo
studies.
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discussions.
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